Comparative Potential of the 2-Item Versus the 9-Item Patient Health Questionnaire to Predict Death or Rehospitalization in Heart Failure
Depression is common in heart failure and associated with adverse clinical outcomes. We investigated the potential of the 2-item patient health questionnaire (PHQ-2) versus that of the 9-item version (PHQ-9) to predict death or rehospitalization.
Methods and Results—
Participants of the Interdisciplinary Network for Heart Failure program were eligible, if they completed the PHQ-9 during baseline assessment. All participants were hospitalized for cardiac decompensation and had a left ventricular ejection fraction ≤40% before discharge. PHQ-2 scores were extracted from the answers to the first 2 PHQ-9 questions. To analyze associations of PHQ-2 and PHQ-9 with both, death and rehospitalization, univariable Cox regression models were used. To compare screening efficacy of both tools, c-statistics were computed. The sample consisted of 852 patients, (67.6±12.1 years; 27.7% women; 42.3% New York Heart Association class III/IV). Follow-up was 18 months (100% complete). During follow-up, 152 patients died and 482 were rehospitalized. Both, PHQ-2 and PHQ-9, predicted death in univariable analysis (hazard ratio, 1.18; 95% confidence interval, 1.09–1.29; P<0.001 and hazard ratio, 1.07; 95% confidence interval, 1.04–1.09; P<0.001, respectively), as well as rehospitalization (hazard ratio, 1.07; confidence interval, 1.01–1.21; P=0.02 and hazard ratio, 1.03; confidence interval, 1.01–1.04; P=0.001, respectively). These results were confirmed by c-statistics.
In univariable models and confirmed by c-statistics the potential of both PHQ-2 and PHQ-9 to predict death and hospitalization was similar. In clinical practice, PHQ-2 screening seems thus sufficiently reliable and more feasible than the time-consuming PHQ-9 to identify patients at an increased risk of adverse outcomes.
Clinical Trial Registration—
URL: http://www.controlled-trials.com. Unique identifier: ISRCTN 23325295.
A close interrelationship exists between depression and cardiovascular diseases.1 With a prevalence of 20 to >40%, comorbid depression is 2 to 5 times more common in heart failure than in the general population2 and associated with adverse outcomes as reduced quality of life,2,3 increased all-cause mortality,2,4 frequency of rehospitalization,2,4,5 and augmented healthcare costs.2,4 Furthermore, there is evidence to suggest that depression adversely affects adherence to pharmacological and nonpharmacological treatments and healthy lifestyle.6
Clinical Perspective on p 472
Although the definite diagnosis of depression requires a structured interview, several validated self-assessment questionnaires may ease detection. The 9-item patient health questionnaire (PHQ-9) is a commonly used instrument facilitating not only diagnosis but also estimation of severity of depressive symptoms7,8 (Data Supplement). Depression as assessed by the PHQ-9 was recently shown to independently predict healthcare use and mortality in patients with heart failure,4 and predicted rehospitalization in subjects with various cardiovascular disorders.9
In routine care, depression remains often undiagnosed,10 and guidelines for specific therapy are lacking in cardiovascular diseases. Reports on depression management in heart failure are scarce. The Sertraline Against Depression and Heart Disease in Chronic Heart Failure (SADHART-CHF) study tested for 12 weeks the selective serotonin antagonist sertraline against placebo.11 As in previous trials in coronary disease (overview in study by Angermann et al12), no specific antidepressant effect was found. The Heart Failure-A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) trial showed that aerobic exercise improved depressive symptoms significantly, but only modestly.13 Results of the Effects of Selective Serotonin Re-uptake Inhibition on Morbidity, Mortality, and Mood in Depressed Heart Failure Patients (MOOD-HF) study,12 which evaluates long-term effects of escitalopram on mortality and morbidity, are still pending. Management models, in which clinical care is tailored to individual needs seem promising because they improved mental health-related quality of life14 and survival.15 Broader appreciation of the relevance of this comorbidity might enhance development of more targeted treatment strategies, and routine screening for depression in heart failure might be a first step to approach this goal.
The PHQ-2 consists of only the first 2 PHQ-9 items.16 Its completion took less than a minute in an earlier study, whereas longer questionnaires proved more time-consuming and cumbersome to score.17 Thus, this instrument can easily be applied in routine care. It was previously recommended for depression screening after myocardial infarction18 and identified in the Heart and Soul Study subjects at increased risk for adverse cardiovascular outcomes with good specificity.19
Rollman et al20 recently demonstrated an increased mortality risk in patients with heart failure, in whom depression was suspected on clinical grounds, and who endorsed one or both PHQ-2 items compared with those who responded negatively to both. To date, this instrument has not been explored in unselected patients with heart failure, however, and it is unknown how the prognostic performance of the shorter PHQ-2 compares with that of the PHQ-9 in such populations.
We studied a large consecutive cohort of patients hospitalized for acute cardiac decompensation, who underwent psychometric assessment before discharge. Our primary aim was to evaluate the predictive potential of PHQ-2 scores about both all-cause mortality and rehospitalization risk versus that of the PHQ-9 scores. To aid interpretation of the PHQ screening results, we further aimed to describe in this population the association of depressive symptoms according to PHQ screening with various patient characteristics and the relation of these variables to outcomes.
Study Flow and Patients
The Interdisciplinary Network for Heart Failure (INH) program evaluated effects and mode of action of a nurse-coordinated telephone-based disease management program (Heart-NetCare-HF) in patients previously hospitalized for cardiac decompensation (unique trial identifier: ISRCTN 23325295) at 9 study sites. Details of study design, end points, and patient characteristics were previously published.21 The INH study protocol conformed with the Declaration of Helsinki, and was approved by all responsible ethics committees. All participants of the present post hoc analysis were recruited according to INH inclusion and exclusion criteria,21 and provided written informed consent.
Patients were eligible, if aged >18 years and hospitalized with signs and symptoms of decompensated heart failure, and if their left ventricular ejection fraction was ≤40% before discharge from hospital. The only exclusion criteria were new-onset structural heart disease as the primary cause of cardiac decompensation and inability or unwillingness of the patient or logistic reasons precluding participation in a telephone-based healthcare intervention. We report on consecutive patients undergoing depression screening with the PHQ-9 during the INH baseline assessment. Follow-up about all-cause death and rehospitalization was 18 months (100% complete).
Baseline Examination and Depression Assessment
Patients underwent a standardized clinical evaluation, including medical history, physical status, assessment of comorbidities, laboratory testing, ECG, and quantitative echocardiography. Depressive symptoms were assessed using the German version of the PHQ-9, which evaluates the intensity of 9 symptoms reflecting the diagnostic criteria for a depressive episode according to the Diagnostic and Statistical Manual of Mental Disorders IV, and represents an established tool for depression screening in cardiovascular disease.22 The abbreviated PHQ-2 contains only the first 2 questions of the PHQ-9 and has also been validated in different languages, including German.23 It is regarded as a simple, rapidly to administer proxy of the more time consuming diagnostic interview for depression diagnosis and assessment of severity.16,23 Both tools refer to symptoms in the last 2 weeks. The answer “not at all” scores 0, “on several days” scores 1, “on more than half of the days” scores 2, and “nearly every day” scores 3, respectively. Overall scores may thus range from 0 to 27 (PHQ-9) and from 0 to 6 score points (PHQ-2), respectively. An American Heart Association Science Advisory recommended further evaluation of PHQ-2 positive cases using the PHQ-9.18 We extracted the PHQ-2 scores ex post from the PHQ-9 results.
End points of this post hoc analysis were time to all-cause death or rehospitalization. Eighteen months after the baseline assessment vital status was ascertained in all patients either by a follow-up examination in the INH outpatient clinics or by structured telephone follow-up, which was performed by a trained nurse or a physician. Records of general practitioners or cardiologists, hospital discharge letters, reports from patients and relatives, and death certificates were used as source documents to assess hospital readmissions and to determine the date of death in deceased patients.
Data Analysis and Statistics
Baseline demographics, physical status, symptoms, and diagnostic variables were compared according to PHQ-2 scores, using Kruskal–Wallis testing for continuous and Pearson χ2 testing for categorical variables. To evaluate the association of continuous PHQ-2 and PHQ-9 scores with outcomes Cox proportional hazard regression analyses were used, and hazard ratios (HRs) with 95% confidence intervals (CIs) calculated.
According to literature16,22,24 patients were dichotomized in a nondepressed group (PHQ-2=0–2, and PHQ-9=0–9 score points, respectively) and a group suspected to currently have depression (depressed, PHQ-2>2, and PHQ-9>9 score points, respectively) to allow calculation of univariable HRs for all-cause mortality and rehospitalization. To visualize the analyses Kaplan–Meier curves were created. To demonstrate their correspondence we used cross-tabulation of categorical PHQ-2 versus categorical PHQ-9 results.
To describe the association between different degrees of depression severity and the frequency of various patient characteristics patients were allocated by PHQ-2 scores to 4 subgroups with 0, 1 to 2, 3 to 4, and 5 to 6 score points. To compare all-cause mortality and rehospitalization in these subgroups Kaplan–Meier curves were created.
For prediction models of all-cause mortality and rehospitalization risk Harrell c-statistics25 were calculated from the PHQ-2 and PHQ-9 scores, respectively, both unadjusted and adjusted for age, sex, and treatment allocation. The 95% CI and P values for the test against 0.5 were computed using the Jackknife method.26 Using the same approach, differences between c-statistics of the models for PHQ-2 and PHQ-9 were analyzed. To visualize the comparative predictive value of PHQ-2 versus PHQ-9, receiver-operating characteristic curves were computed.
IBM SPSS version 21.0 software (Armonk, NY) was used for the statistical analyses. A 2-tailed P<0.05 was considered significant.
Of 1022 consecutive patients recruited according to INH inclusion criteria 852 participated in the psychometric assessment and were included in this analysis. Baseline characteristics of this study population and of the 4 subgroups composed according to the baseline PHQ-2 scores are displayed in Table 1. As a whole, patients were elderly and predominantly men, and the most common pathogenesis of heart failure was coronary artery disease. Subjects with higher PHQ-2 scores were older, had a lower ejection fraction, and were more often on treatment with diuretics and less frequently on β-blockers. Furthermore, chronic obstructive pulmonary disease and more severe symptoms (ie, New York Heart Association [NYHA] functional classes III–IV) were more common in the subgroups with higher PHQ-2 scores, who also had higher amino-terminal pro-B-type natriuretic peptide levels and tended to have more often diabetes mellitus. Elevated depressive symptoms were observed in 33.5% of the patients based on PHQ-2 scores >2 or PHQ-9 scores >9, respectively. Table 2 shows frequencies of categorical PHQ-2 and PHQ-9 values to demonstrate their correspondence. The Spearman correlation coefficient between PHQ-2 and PHQ-9 scores was 0.85 (P<0.001).
|All Patients (n=852)||PHQ-2=0 (n=199)||PHQ-2=1–2 (n=368)||PHQ-2=3–4 (n=199)||PHQ-2=5–6 (n=86)||P Value|
|Age, y, mean (SD)||67.6 (12.1)||64.9 (13.4)||67.0 (12.4)||67.9 (11.8)||69.22 (11.8)||0.03|
|Female sex, n (%)||236 (27.7)||52 (26.1)||95 (25.8)||56 (28.1)||33 (38.4)||0.12|
|Predominant heart failure pathogenesis (n, %)|
|Coronary artery disease||425 (49.9)||107 (53.8)||184 (50.0)||93 (46.7)||41 (47.7)||0.54|
|Others||427 (50.1)||92 (46.2)||184 (50.0)||106 (53.3)||45 (52.3)||…|
|Comorbidities (n, %)|
|COPD*||149 (17.5)||21 (10.6)||57 (15.5)||41 (20.6)||30 (34.9)||<0.001|
|Diabetes mellitus||290 (34.0)||55 (27.6)||128 (34.8)||80 (40.2)||27 (31.4)||0.06|
|Renal dysfunction†||337 (39.6)||73 (36.7)||135 (36.7)||90 (45.2)||39 (45.3)||0.12|
|History of depression||92 (10.8)||7 (3.5)||32 (8.7)||34 (17.1)||19 (22.1)||<0.001|
|NYHA functional class|
|I–II, n (%)||492 (57.7)||145 (72.9)||225 (61.1)||95 (47.7)||27 (31.4)||<0.001|
|III-IV, n (%)||360 (42.3)||54 (27.1)||143 (38.9)||104 (52.3)||59 (68.6)||…|
|LVEF <30%, (n, %)‡||410 (49.3)||82 (41.6)||178 (49.7)||100 (52.1)||50 (58.8)||0.04|
|Mean arterial pressure, mm Hg, mean (SD)§||86.7 (12.0)||88 (11.8)||87.5 (12.1)||87 (11.9)||85.8 (11.9)||0.37|
|NT-proBNP, pg/mL, median (IQR)||2807 (5640.0)||2203 (4246.0)||2509 (5497.0)||3829 (6838.0)||4067 (7534.0)||0.01|
|Creatinine, mmol/L, median (IQR)||97.2 (44.2)||97.2 (0.4)||97.2 (35.4)||97.2 (44.2)||97.2 (44.2)||0.84|
|Therapy (n, %)|
|Diuretics||737 (86.5)||161 (80.9)||322 (87.5)||172 (86.4)||82 (95.3)||0.01|
|β-blocker||716 (84.0)||171 (85.9)||323 (87.8)||154 (77.4)||68 (79.1)||0.01|
|ACEi/ARB||764 (89.7)||179 (89.9)||331 (89.9)||173 (86.9)||81 (94.2)||0.32|
|Antidepressants||65 (7.6)||4 (2.0)||27 (7.3)||21 (10.6)||13 (15.1)||<0.001|
|Allocation to HNC||420 (49.3)||105 (52.8)||188 (51.1)||87 (43.7)||40 (46.5)||0.24|
|n (%)||n (%)||n (%)|
|PHQ-2||0–2||510 (59.8)||57 (6.7)||567 (66.5)|
|3–6||57 (6.7)||228 (26.8)||285 (33.5)|
|Total||567 (66.5)||285 (33.5)||852 (100)|
Mortality Risk According to PHQ Results
During the 18-month follow-up period, 152 (17.8%) of the study participants died. Both, PHQ-2 and PHQ-9 scores were significant predictors of all-cause mortality risk (HR, 1.18; 95% CI, 1.09–1.29; P<0.001 and HR, 1.07; 95% CI, 1.04–1.09; P<0.001, respectively). According to the dichotomized PHQ scores, mortality risk was significantly higher in patients with elevated depressive symptoms (PHQ-2 score >2 and PHQ-9 score >9) than in patients scoring only ≤2 points in the PHQ-2 and ≤9 points in the PHQ-9, respectively (PHQ-2: HR, 1.70; 95% CI, 1.23–2.33; P=0.001 and PHQ-9: HR, 2.09; 95% CI, 1.52–2.87; P<0.001).
Kaplan–Meier survival curves of dichotomized PHQ-2 and PHQ-9 scores of nondepressed patients versus those, whose scores indicated current depressive episode, are superimposed on each other in Figure 1A. The close vicinity of the PHQ-2 and PHQ-9 curve pairs in each of the 2 subpopulations indicates comparable potential of both questionnaires to predict the risk of all-cause death.
Rehospitalization Risk According to PHQ Results
Four hundred eighty-two patients (56.6%) were rehospitalized at least once during the 18-month follow-up period. Both PHQ-2 and PHQ-9 scores proved significant predictors of rehospitalization risk in univariable analysis (HR, 1.07; 95% CI, 1.01–1.21; P=0.02, and HR, 1.03; 95% CI, 1.01–1.04; P=0.001, respectively). All-cause rehospitalization risk proved significantly increased for the PHQ-9 dichotomized at >9 score points (HR, 1.30; 95% CI, 1.04–1.51; P=0.02), but not for the PHQ-2 dichotomized at >2 score points (HR, 1.14; 95% CI, 0.95–1.38; P=0.17). Figure 1B depicts the Kaplan–Meier curves for dichotomized PHQ-2 and PHQ-9 scores in the nondepressed versus the depressed subjects to demonstrate their comparative predictive potential also about this end point.
Patient Baseline Characteristics and Prognosis
Table 3 displays associations of the baseline characteristics (as displayed in Table 1) with all-cause mortality and rehospitalization; whereas ischemic pathogenesis, parameters of heart failure severity, various comorbidities, and treatment with diuretics and antidepressants were associated with an increased HR, treatment with angiotensin-converting enzyme inhibitors or angiotensin-2 receptor blockers and β-blockers reduced the HR for both outcomes. Some of the correlates of elevated PHQ-2 scores presented in Table 1 were also associated with increased HRs for all-cause death and rehospitalization.
|HR||95% CI||P Value||HR||95% CI||P Value|
|Age, per decade||1.59||1.36–1.86||<0.001||1.25||1.15–1.35||<0.001|
|Female vs male sex||1.15||0.82–1.63||0.42||1.05||0.86–1.28||0.63|
|Predominant heart failure pathogenesis|
|Coronary artery disease as cause of heart failure vs other causes||1.37||1.00–1.89||0.05||1.28||1.07–1.53||0.01|
|Comorbidities (yes vs no)|
|History of depression||2.85||1.95–4.15||<0.001||1.44||1.11–1.88||0.01|
|NYHA functional class|
|III/IV vs I/II||2.82||2.02–3.94||<0.001||1.59||1.33–1.89||<0.001|
|LVEF <30%‡, yes vs no||1.33||0.97–1.83||0.08||1.10||0.92–1.32||0.30|
|Mean arterial pressure§, per increase of 5 mm Hg||0.94||0.87–1.01||0.08||0.96||0.92–1.01||0.07|
|NT-proBNP, per 1000 pg/mL increase||1.06||1.01–1.11||0.03||1.02||1.01–1.03||<0.001|
|Creatinine, per 0.1 mmol/L increase||1.30||1.15–1.48||<0.001||1.16||1.06–1.27||0.001|
|Therapy (yes vs no)|
|Allocation to HNC||0.77||0.56–1.07||0.12||1.04||0.87–1.24||0.71|
Comparability of the 2-Item Versus the 9-Item PHQ
The c-statistics for the prediction of all-cause mortality and rehospitalization risk, both unadjusted and adjusted for age, sex, and treatment allocation, are given in Table 4. No significant differences between the predictive values of PHQ-2 and PHQ-9 scores were evident. To visualize their relationship, receiver-operating characteristic curves for PHQ-2 and PHQ-9 scores were created (Figure 2A and 2B), which demonstrate the comparable performance of both questionnaires about prediction of all-cause death, but also a somewhat inferior predictive potential of the PHQ-2 about rehospitalization.
|C-Statistics||95% CI||P Value|
|C-statistics for the Prediction of All-Cause Mortality Risk|
|Difference between PHQ-9 and PHQ-2||0.009||−0.190 to +0.360||0.53|
|PHQ-2||0.667||0.620 to 0.710||<0.001|
|PHQ-9||0.674||0.630 to 0.720||<0.001|
|Difference between PHQ-9 and PHQ-2||0.007||−0.010 to +0.020||0.28|
|C-statistics for the prediction of rehospitalization risk|
|PHQ-2||0.533||0.502 to 0.565||0.04|
|PHQ-9||0.539||0.510 to 0.568||0.008|
|Difference between PHQ-9 and PHQ-2||0.006||−0.012 to +0.023||0.52|
|PHQ-2||0.573||0.546 to 0.600||<0.001|
|PHQ-9||0.579||0.552 to 0.606||<0.001|
|Difference between PHQ-9 and PHQ-2||0.006||−0.002 to +0.013||0.14|
Severity of Depressive Symptoms and Prognosis
Figure 3A and 3B depict Kaplan–Meier curves for survival and freedom of rehospitalization in the 4 subgroups composed according to the PHQ-2 scores. Compared with the referent subgroup, these curves suggest a dose–response relationship between the severity of the depressive symptoms and the risk of all-cause death, whereas only patients scoring 5 to 6 points exhibited also a significantly increased risk of rehospitalization.
In this analysis of a large, consecutive sample of patients hospitalized for an episode of acute decompensation because of systolic heart failure, we demonstrated that not only PHQ-9 scores but also the PHQ-2 scores obtained at baseline were associated with an increased risk of all-cause death and rehospitalization in the subsequent 18 months. The capacity of the shorter PHQ-2 to identify patients at increased risk was similar to that of the longer and more time-consuming PHQ-9.
Comparability of the 2-Item and the 9-Item PHQ
When dichotomizing our patient population in a nondepressed group and a group with suspected clinically relevant depressive symptoms using cut-off scores as previously proposed16,22,24 the prevalence of depression was 33.5% (n=285) according to the PHQ-2 as well as PHQ-9 screening results. As indicated by previous meta-analysis,27 prevalence rates of comorbid depression among hospitalized patients vary considerably. Part of this variability is probably because of the use of different instruments and cutoffs for depression assessment. With our definitions and cutoffs depression prevalence proved comparable with both instruments reconfirming also that depression is one of the most frequent comorbidities in heart failure.2
Kaplan–Meier survival curves for subpopulations with and without a suspected episode of current depression showed that both, PHQ-2 and PHQ-9 results predicted mortality risk in a comparable fashion. They also indicated a significantly higher mortality risk in the depressed group. High rehospitalization rates in the first 3 months post discharge in both subpopulations indicated that factors other than depression were in this period primary determinants of that outcome. From month 4 onwards rehospitalization declined more in the nondepressed than the depressed subjects. Because this difference remained small in absolute terms, however, the clinical relevance of the lower predictive power observed with PHQ-2 screening seems negligible.
C-statistics comparing PHQ-2 and PHQ-9 confirmed that the loss of prognostic power was small and nonsignificant when PHQ-2 instead of PHQ-9 scores were used for depression assessment. Furthermore, direct comparison of the corresponding receiver-operating characteristic curves showed comparable predictive values.
Like previous studies in patients with cardiovascular diseases,28,29 which used the Beck Depression Inventory as a psychometric tool, PHQ screening identified patients at risk for all-cause death and rehospitalization. Our results are in line with recent findings by Moraska et al4 who using the PHQ-9 with a cut-off score of >10 as depression criterion reported a 4-fold increase in all-cause mortality and nearly 2-fold increased hospitalization rate in the highest quartile of a large heart failure cohort during a mean follow-up of 1.6 years. Our study extends these findings to the PHQ-2. Rollman et al20 failed to demonstrate a dose–response relationship when applying the PHQ-2 in patients with heart failure, in whom depression was already suspected on clinical grounds. The authors considered this as a possible consequence of clinical prescreening, which rendered only high-risk patients eligible for enrolment. More congruent with our results, Beach et al9 found in a secondary analysis from a depression management trial30 in subjects with various cardiac disorders that higher initial depression scores were also associated with higher cardiac readmission rates at 6 months.
Correlates of Depression and Predictive Relevance of Patient Baseline Characteristics
Various features of the heart failure syndrome were previously identified as depression correlates, such as comorbidities, low left ventricular ejection fraction, and severity of heart failure symptoms,31 and our results strengthen these observations. Meta-analysis demonstrated a rise of aggregate depression rates from 11% in NYHA class I to 42% in NYHA class IV.2 In accordance with this observation, prevalence and severity of depression according to PHQ-2 scores were associated with the severity of heart failure symptoms in our analysis because >50% of patients scoring 3 or 4 and almost 70% of patients scoring 5 or 6 points were in NYHA class III or IV, whereas the majority of subjects with lower scores were in NYHA class I or II. Among the postulated mediators involved in the reciprocal adverse effects of cardiovascular disorders and their comorbidities and depression the degree of dysregulation of autonomic nervous control, the level of circulating catecholamines, the extent of activation of inflammatory, oxidative, and nitrosative pathways and increased hemodynamic stress are recognized markers of heart failure severity.32 Vice versa, NYHA class is a strong predictor of incident depression.6 Furthermore, increasing depressive symptoms were associated with worsening heart failure,33 and depression remission was associated with improved cardiac outcomes.34 Last but not least, outcomes may be modulated by behavioral risk factors as unhealthy lifestyle habits,6 nonadherence to treatment and lack of social support.31
Although our present observations are in accordance with the concept of a pathophysiological link between heart failure and depression, not all patient characteristics with adverse prognostic significance correlated also with higher depression scores. Coronary artery disease was, for example, associated with an increased HR for both, death and rehospitalization, but not with higher PHQ scores. Although treatment with angiotensin-converting enzyme inhibitors or angiotensin-2 receptor blockers and β-blockers improved outcomes significantly, heart failure medication was not consistently associated with lower depression scores. To what extent the correlation of depression history and use of antidepressants or diuretics with higher PHQ-2 scores and concomitant higher HRs for adverse outcomes relates to more severe depression or heart failure or to unwanted drug effects cannot be clarified from our data. Altogether our results indicate, however, a partial overlap between the effects of depression and those of clinical prognosticators.
Depression—Rarely Diagnosed in Heart Failure
Before the index hospitalization, depression was unknown in the majority of patients because only 17.1% of participants scoring 3 to 4 and 22.1% of those scoring 5 to 6 at PHQ-2 screening reported a history of depression, and even less, 10.6% and 15.1%, were on antidepressants, which may, however, also reflect the lack of evidence-based pharmacotherapy. Compared with a contemporary American cohort described by Moraska et al4 these proportions are even smaller, thus re-emphasizing the need for better understanding of the pathophysiological links between cardiovascular disease and comorbid depression and better appreciation of this comorbidity in clinical practice. Patients with heart failure may often misinterpret emotional distress as integral part of their heart disease, or are reluctant to communicate such feelings for fear of being labeled as mentally ill. In turn, cardiologists and general practitioners may lack adequate training and time to diagnose comorbid depression. It is essential that both, patients and physicians recognize that depressive symptoms are not an integral component of the heart failure syndrome. Routine PHQ-2 screening bears the promise of raising this awareness.
Limitations and Strengths
Several limitations of this study must be acknowledged. First, self-reports on depression were not confirmed by structured clinical interview, which must remain the gold standard for depression diagnosis. However, this study aimed primarily to assess the capability of the PHQ-2 compared with the PHQ-9 to identify patients at increased risk of mortality and rehospitalization. To this end, recognition of depression using these tools seemed more important than precise quantification of the depressive symptoms. Moreover, in a previous validation study, PHQ screening results compared favorably also with the structured clinical interview.22 Another limitation is that only patients with impaired left ventricular ejection fraction were enrolled. Our findings can, therefore, not be generalized to the entire heart failure population. We further applied a limited number of exclusion criteria, and not all patients enrolled in the INH study followed the invitation for psychometric evaluation. We can thus not exclude that patients eligible and willing to complete the questionnaires differed from nonparticipants. Strengths of our study include the large sample size and the prospective nature of the protocol, precise characterization of the study cohort and careful end point collection and assessment. Eighteen months follow-up was 100% complete, all hospital admissions were assessed from discharge letters, and information on death was collected from hospital records, death certificates, and reports from relatives and physicians.
In this large consecutive cohort evaluated before hospital discharge after an episode of acute cardiac decompensation, the potential of the PHQ-2 to identify patients at increased risk for death and rehospitalization proved comparable with that of the longer PHQ-9. Depression severity as assessed by the PHQ-2 correlated with various patient characteristics, and a dose–response relationship between PHQ-2 scores and the risk of mortality and rehospitalization was demonstrated. Among the patient characteristics, which correlated with elevated PHQ-2 scores, some were also associated with an increased HR for all-cause death and rehospitalization indicating a partial overlap of depression effects with those of clinical prognosticators. Because better knowledge about patients’ mood might thus aid risk stratification and potentially help to improve patient management, depression screening should become part of the routine clinical assessment of patients with heart failure. Our results demonstrate that the PHQ-2 represents a suitable tool for this purpose.
Sources of Funding
This study was supported by
Davidson KW, Rieckmann N, Clemow L, Schwartz JE, Shimbo D, Medina V, Albanese G, Kronish I, Hegel M, Burg MMEnhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies randomized controlled trial.Arch Intern Med. 2010; 170:600–608. doi: 10.1001/archinternmed.2010.29.CrossrefMedlineGoogle Scholar
Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJDepression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes.J Am Coll Cardiol. 2006; 48:1527–1537. doi: 10.1016/j.jacc.2006.06.055.CrossrefMedlineGoogle Scholar
Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, Whooley MADepressive symptoms and health-related quality of life: the Heart and Soul Study.JAMA. 2003; 290:215–221. doi: 10.1001/jama.290.2.215.CrossrefMedlineGoogle Scholar
Moraska AR, Chamberlain AM, Shah ND, Vickers KS, Rummans TA, Dunlay SM, Spertus JA, Weston SA, McNallan SM, Redfield MM, Roger VLDepression, healthcare utilization, and death in heart failure: a community study.Circ Heart Fail. 2013; 6:387–394. doi: 10.1161/CIRCHEARTFAILURE.112.000118.LinkGoogle Scholar
Frasure-Smith N, Lespérance F, Irwin MR, Sauvé C, Lespérance J, Théroux PDepression, C-reactive protein and two-year major adverse cardiac events in men after acute coronary syndromes.Biol Psychiatry. 2007; 62:302–308. doi: 10.1016/j.biopsych.2006.09.029.CrossrefMedlineGoogle Scholar
Lossnitzer N, Herzog W, Störk S, Wild B, Müller-Tasch T, Lehmkuhl E, Zugck C, Regitz-Zagrosek V, Pankuweit S, Maisch B, Ertl G, Gelbrich G, Angermann CE; Competence Network Heart Failure. Incidence rates and predictors of major and minor depression in patients with heart failure.Int J Cardiol. 2013; 167:502–507. doi: 10.1016/j.ijcard.2012.01.062.CrossrefMedlineGoogle Scholar
Löwe B, Kroenke K, Herzog W, Gräfe KMeasuring depression outcome with a brief self-report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9).J Affect Disord. 2004; 81:61–66. doi: 10.1016/S0165-0327(03)00198-8.CrossrefMedlineGoogle Scholar
Kroenke K, Spitzer RL, Williams JBThe PHQ-9: validity of a brief depression severity measure.J Gen Intern Med. 2001; 16:606–613.CrossrefMedlineGoogle Scholar
Beach SR, Januzzi JL, Mastromauro CA, Healy BC, Beale EE, Celano CM, Huffman JCPatient Health Questionnaire-9 score and adverse cardiac outcomes in patients hospitalized for acute cardiac disease.J Psychosom Res. 2013; 75:409–413. doi: 10.1016/j.jpsychores.2013.08.001.CrossrefMedlineGoogle Scholar
Holzapfel N, Zugck C, Müller-Tasch T, Löwe B, Wild B, Schellberg D, Nelles M, Remppis A, Katus H, Herzog W, Jünger JRoutine screening for depression and quality of life in outpatients with congestive heart failure.Psychosomatics. 2007; 48:112–116. doi: 10.1176/appi.psy.48.2.112.CrossrefMedlineGoogle Scholar
O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, Zakhary B, Stough WG, Arias RM, Rivelli SK, Krishnan R; SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial.J Am Coll Cardiol. 2010; 56:692–699. doi: 10.1016/j.jacc.2010.03.068.CrossrefMedlineGoogle Scholar
Angermann CE, Gelbrich G, Störk S, Fallgatter A, Deckert J, Faller H, Ertl G; MOOD-HF Investigators. Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF).Eur J Heart Fail. 2007; 9:1212–1222. doi: 10.1016/j.ejheart.2007.10.005.CrossrefMedlineGoogle Scholar
Blumenthal JA, Babyak MA, O’Connor C, Keteyian S, Landzberg J, Howlett J, Kraus W, Gottlieb S, Blackburn G, Swank A, Whellan DJEffects of exercise training on depressive symptoms in patients with chronic heart failure: the HF-ACTION randomized trial.JAMA. 2012; 308:465–474. doi: 10.1001/jama.2012.8720.CrossrefMedlineGoogle Scholar
Huffman JC, Mastromauro CA, Beach SR, Celano CM, Dubois CM, Healy BC, Suarez L, Rollman BL, Januzzi JLCollaborative care for depression and anxiety disorders in patients with recent cardiac events: The Management Of Sadness and Anxiety In Cardiology (MOSAIC) randomized clinical trial.JAMA Intern Med. 2014; 174:927–935. doi: 10.1001/jamainternmed.2014.739.CrossrefMedlineGoogle Scholar
Gelbrich G, Störk S, Kreißl-Kemmer S, Faller H, Prettin C, Heuschmann PU, Ertl G, Angermann CEEffects of structured heart failure disease management on mortality and morbidity depend on patients’ mood: results from the Interdisciplinary Network for Heart Failure Study.Eur J Heart Fail. 2014; 16:1133–1141. doi: 10.1002/ejhf.150.CrossrefMedlineGoogle Scholar
Kroenke K, Spitzer RL, Williams JBThe Patient Health Questionnaire-2: validity of a two-item depression screener.Med Care. 2003; 41:1284–1292. doi: 10.1097/01.MLR.0000093487.78664.3C.CrossrefMedlineGoogle Scholar
Whooley MA, Avins AL, Miranda J, Browner WSCase-finding instruments for depression. Two questions are as good as many.J Gen Intern Med. 1997; 12:439–445.CrossrefMedlineGoogle Scholar
Lichtman JH, Bigger JT, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lespérance F, Mark DB, Sheps DS, Taylor CB, Froelicher ES; American Heart Association Prevention Committee of the Council on Cardiovascular Nursing; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention; American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research; American Psychiatric Association. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association.Circulation. 2008; 118:1768–1775. doi: 10.1161/CIRCULATIONAHA.108.190769.LinkGoogle Scholar
Elderon L, Smolderen KG, Na B, Whooley MAAccuracy and prognostic value of American Heart Association: recommended depression screening in patients with coronary heart disease: data from the Heart and Soul Study.Circ Cardiovasc Qual Outcomes. 2011; 4:533–540. doi: 10.1161/CIRCOUTCOMES.110.960302.LinkGoogle Scholar
Rollman BL, Herbeck Belnap B, Mazumdar S, Houck PR, He F, Alvarez RJ, Schulberg HC, Reynolds CF, McNamara DMA positive 2-item Patient Health Questionnaire depression screen among hospitalized heart failure patients is associated with elevated 12-month mortality.J Card Fail. 2012; 18:238–245. doi: 10.1016/j.cardfail.2011.11.002.CrossrefMedlineGoogle Scholar
Angermann CE, Störk S, Gelbrich G, Faller H, Jahns R, Frantz S, Loeffler M, Ertl G; Competence Network Heart Failure. Mode of action and effects of standardized collaborative disease management on mortality and morbidity in patients with systolic heart failure: the Interdisciplinary Network for Heart Failure (INH) study.Circ Heart Fail. 2012; 5:25–35. doi: 10.1161/CIRCHEARTFAILURE.111.962969.LinkGoogle Scholar
Löwe B, Spitzer RL, Gräfe K, Kroenke K, Quenter A, Zipfel S, Buchholz C, Witte S, Herzog WComparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians’ diagnoses.J Affect Disord. 2004; 78:131–140.CrossrefMedlineGoogle Scholar
Löwe B, Kroenke K, Gräfe KDetecting and monitoring depression with a two-item questionnaire (PHQ-2).J Psychosom Res. 2005; 58:163–171. doi: 10.1016/j.jpsychores.2004.09.006.CrossrefMedlineGoogle Scholar
Manea L, Gilbody S, McMillan DOptimal cut-off score for diagnosing depression with the Patient Health Questionnaire (PHQ-9): a meta-analysis.CMAJ. 2012; 184:E191–E196. doi: 10.1503/cmaj.110829.CrossrefMedlineGoogle Scholar
Harrell FE, Lee KL, Mark DBMultivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.Stat Med. 1996; 15:361–387. doi: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4.CrossrefMedlineGoogle Scholar
Abdi H, Williams LJBarycentric discriminant analysis (BADIA). , Salkind NJ, In: Encyclopedia of Research Design: Thousand Oaks, CA: Sage; 2010:64–75.Google Scholar
Rutledge T, Redwine LS, Linke SE, Mills PJA meta-analysis of mental health treatments and cardiac rehabilitation for improving clinical outcomes and depression among patients with coronary heart disease.Psychosom Med. 2013; 75:335–349. doi: 10.1097/PSY.0b013e318291d798.CrossrefMedlineGoogle Scholar
Adams J, Kuchibhatla M, Christopher EJ, Alexander JD, Clary GL, Cuffe MS, Califf RM, Krishnan RR, O’Connor CM, Jiang WAssociation of depression and survival in patients with chronic heart failure over 12 Years.Psychosomatics. 2012; 53:339–346. doi: 10.1016/j.psym.2011.12.002.CrossrefMedlineGoogle Scholar
Lespérance F, Frasure-Smith N, Talajic M, Bourassa MGFive-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction.Circulation. 2002; 105:1049–1053.LinkGoogle Scholar
Huffman JC, Mastromauro CA, Sowden GL, Wittmann C, Rodman R, Januzzi JLA collaborative care depression management program for cardiac inpatients: depression characteristics and in-hospital outcomes.Psychosomatics. 2011; 52:26–33. doi: 10.1016/j.psym.2010.11.021.CrossrefMedlineGoogle Scholar
Angermann CE, Gelbrich G, Störk S, Schowalter M, Deckert J, Ertl G, Faller H; Competence Network Heart Failure. Somatic correlates of comorbid major depression in patients with systolic heart failure.Int J Cardiol. 2011; 147:66–73. doi: 10.1016/j.ijcard.2009.07.044.CrossrefMedlineGoogle Scholar
Wallenborn J, Angermann CEComorbid depression in heart failure.Herz. 2013; 38:587–596. doi: 10.1007/s00059-013-3886-z.CrossrefMedlineGoogle Scholar
Sherwood A, Blumenthal JA, Hinderliter AL, Koch GG, Adams KF, Dupree CS, Bensimhon DR, Johnson KS, Trivedi R, Bowers M, Christenson RH, O’Connor CMWorsening depressive symptoms are associated with adverse clinical outcomes in patients with heart failure.J Am Coll Cardiol. 2011; 57:418–423. doi: 10.1016/j.jacc.2010.09.031.CrossrefMedlineGoogle Scholar
Jiang W, Krishnan R, Kuchibhatla M, Cuffe MS, Martsberger C, Arias RM, O’Connor CM; SADHART-CHF Investigators. Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study).Am J Cardiol. 2011; 107:545–551. doi: 10.1016/j.amjcard.2010.10.013.CrossrefMedlineGoogle Scholar
With a prevalence of 20% to 40%, depression is much more common in heart failure than in the general population, and associated with adverse outcomes. Although validated self-assessment questionnaires are available to ease detection, this comorbidity remains often undiagnosed. We studied 852 consecutive patients hospitalized for acute cardiac decompensation, who underwent psychometric assessment before discharge to (1) evaluate the predictive potential of the 2-item Patient Health Questionnaire (PHQ-2) about both all-cause mortality and rehospitalization risk versus that of the longer 9-item version (PHQ-9), and (2) describe the association of depressive symptoms according to PHQ screening with various patient characteristics and the relation of these variables to outcomes. Both PHQ-2 and PHQ-9 predicted death and rehospitalization in univariable analysis, and comparability of their results was confirmed by c-statistics and comparison of receiver-operating characteristic curves. Depression severity as assessed by the PHQ-2 correlated further with various patient characteristics and features of the heart failure syndrome, and a dose–response relationship between PHQ-2 scores, mortality and rehospitalization was shown. Among the patient characteristics, which correlated with elevated PHQ-2 scores some were also associated with an increased hazard ratio for all-cause death and rehospitalization indicating partial overlap of depression effects with a variety of clinical prognosticators. Because better knowledge about patients’ mood may thus aid risk stratification and potentially help to improve patient management, screening for depression should become part of the routine clinical assessment of patients with heart failure. Our results demonstrate that the 2-item PHQ represents a suitable tool for this purpose.